Paeonol Ameliorates Ovalbumin-Induced Asthma through the Inhibition of TLR4/NF-κB and MAPK Signaling

Table 1

The change of inflammatory factors and total inflammatory cells.

Group	IL-4 (pg/mL) in BALF	IFN-γ (pg/mL) in BALF	TGF-β (pg/mL) in BALF	MIP-1β (pg/mL) in BALF	Serum IgE (ng/mL)	No. of infiltrated cells in BALF (10^5/mL)
Con	43.1±5.1	41.2±3.1	22.4±1.5	3.39±1.30	41.2±2.6	2.73±0.20
OVA	88.0±7.3#	20.5±1.9#	32.8±4.1	8.26±2.10#	88.8±5.4#	7.04±1.00#
OVA+Mon	52.0±5.7‡	30.9±3.71†	22.9±2.8	6.89±1.64	54.8±4.9‡	4.21±0.44†
OVA+L-paeonol	75.2±8.1	17.5±2.7	28.0±3.1	6.69±1.46	79.0±5.0	5.07±1.15
OVA+M-paeonol	62.8±4.6†	31.1±4.1†	24.9±4.46	5.11±1.37‡	59.2±5.2‡	2.61±0.30†
OVA+H-paeonol	53.6±6.3‡	34.8±4.3‡	24.2±5.2	4.28±1.33‡	53.7±4.9‡	3.94±1.08‡

Bronchoalveolar lavage fluid, BALF; Macrophage Inflammatory Protein 1 beta, MIP-1β; immunoglobulin E, IgE; ovalbumin, OVA; control, Con; montelukast sodium, Mon. n=6-8; P<0.05, #P<0.01, compared with Con group; †P<0.05, ‡P<0.01, compared with OVA group.